News J&J jumps on the MFN pricing train Johnson & Johnson is the latest pharma group to agree a Most-Favoured Nation (MFN) drug pricing deal with the Trump administration to avert tariffs.
News US vulnerable to China's API dominance, says report China has such a dominant position in pharmaceutical ingredient production that there is a risk it will weaponise access, says a Congressional report.
News Lilly reveals $3bn orforglipron facility in Netherlands After so many announcements of new facility builds in the US, Eli Lilly has made a welcome commitment to a European investment.
News Lilly climbs on stellar GLP-1 drug sales gain Eli Lilly is celebrating a massive 54% increase in its third-quarter revenues to $17.6 billion, driven by its medicines for diabetes and obesity.
News FDA hands out first national priority vouchers to nine firms The FDA has named the first products to take advantage of its recently announced Commissioner's national priority voucher programme.
News JPM: AbbVie pays $650m upfront for RemeGen cancer drug AbbVie joins the ranks of companies developing cancer drugs that target both PD-1 and VEGF, via a $5.6bn licensing deal with China's RemeGen.
Sales & Marketing Sponsored How to meet your physicians where they are online A pharma company’s core mission is to improve patient outcomes. This hinges on effectively influencing HCP clinical behaviour and driving disease education.
